Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Healthy Subjects are eligible for only if all of the following are met: 1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities. 2. Male and female Subjects 45-80 years of age. 3. Have the ability to understand the requirements of the study and is willing to comply with all study procedures. 4. In the opinion of the investigator, able to participate in the study  A Subject is not eligible for if any of the following apply: 1. Receipt of loop diuretics (furosemide, bumetanide or torsemide) or thiazide diuretics (hydrochlorothiazide or metolazone) within 24 hours of study drug. 2. Receipt of potassium-sparing diuretics (spironolactone, amiloride) or oral calcium, potassium or magnesium supplements (including multi-vitamins) within 24 hours of study drug. 3. History of allergy to furosemide, sulfonamides or other loop diuretics. 4. Any skin conditions currently requiring medical therapy. 5. History of diabetes. 6. Presence or need for urinary catheterization, urinary tract abnormality or disorder interfering with urination. 7. Serum sodium <130 mEq/L at screening. 8. Serum potassium < 3.5 or > 5.5 mEq/L at screening. 9. Serum magnesium < 1.5 or > 2.5 mEq/L at screening. 10. Serum chloride < 96 or > 106 mEq/L at screening. 11. Serum calcium < 8.5 or > 10.5 mg/dL at screening. 12. Estimated Glomerular Filtration Rate (GFR) < 30 mL/min/1.73 m2 by simplified Modification of Diet in Renal Disease (sMDRD) equation at screening. 13. Systolic BP (SBP) < 90 mm Hg at screening or baseline. 14. Heart rate > 110 beats per minute (BPM) at screening or baseline. 15. History of tinnitus or hearing impairment, including deafness. 16. Temperature > 38°C (oral or equivalent) at screening or baseline. 17. Blood alcohol concentration > 2 mg/dL (0.02%) at screening or baseline. 18. Female Subject who is pregnant or lactating. 19. History of major abdominal surgery affecting the needle placement site. 20. History of benign prostatic hyperplasia (BPH), prostatitis or prostate cancer. 21. Urinary retention due to bladder emptying disorders and/or urethral narrowing. 22. History of liver disease, cirrhosis, or ascites. 23. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc. 24. Allergies and/or sensitivities to adhesive bandages or medical tape. 25. Any surgical or medical condition which in the opinion of the Investigator may interfere with participation in the study or which may affect the outcome of the study